Subscribe to Updates in Legal, Economic & Regulatory Affairs

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Labor Relations and Union-Management Negotiation Experts (US)

Articles with lock require a subscription to GLG News | Request a free trial
December 2, 2008
Clinical trials held abroad... Implications?
Analysis of: Scrutiny Grows of Drug Trials Abroad | online.wsj.com
Author: GLG Expert Contributor
This article pertains to quality, accrual and safety, but in addition....
Adam FeinDecember 2, 2008
McKesson settlement is next step in the demise of AWP
Analysis of: McKesson Agrees To Settlement In Pricing Suits | online.wsj.com
Author: Adam Fein, Founder & President, Pembroke Consulting Inc
McKesson Corp (MCK) settled its pending class action suit for $351 million and set aside a further $143 million reserve for certain future claims. The settlement removes a source of uncertainty for McKesson, but also signals the beginning of the end for the Average Wholesale Price (AWP) benchmark. Average...
November 26, 2008
UAW Concessions Unlikely to Address U.S. Auto Industry Problems
Analysis of: For UAW, Aid Likely to Come With Strings | online.wsj.com
Author: Richard Block, Professor, Michigan State University
1. Employment reductions in the U.S. auto assembly industry over the past three years have reduced the UAW-hourly represented workforce by roughly half.  As a result, UAW monetary concessions at reasonable levels will not likely contribute substantially to solving the companies' short-rurnfinancial...
November 24, 2008
Avastin and clots? News to me. Black box warning? Why?
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com
Author: GLG Expert Contributor
The exact quote is " Avastin, could raise the risk of blood clots by about 12 percent."
November 24, 2008
GSK's Promacta for ITP: a winner1
Analysis of: PROMACTA (Brand Name Drug) FDA approval 11/20/08 | www.accessdata.fda.gov
Author: GLG Expert Contributor
An oral agent that can be used in patients with ITP that have become refractory to steroids, splenectomy and various immunologic manipulations.
November 19, 2008
Vandetanib (Astra Zeneca): too long at the "Fair?"
Analysis of: Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
A VEGF inhibitor that appears to work well with chemo in non small cell lung carcinoma.
November 17, 2008
Erbitux in Lung Ca- now to predict who will get the skin rash.
Analysis of: Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months | www.pipelinereview.com
Author: GLG Expert Contributor
"New data from pivotal FLEX study reveal that patients treated with Erbitux who develop early skin rash show median overall survival of 15 months (p<0.001)" This is the trial that showed Erbitux + chemo prolonged survival minimally when compared to chemo alone. Now we know the ones who develop a...
Adam FeinNovember 13, 2008
CVS Escalates the Generic Price War
Analysis of: CVS joins generic drug price war | www.upi.com
Author: Adam Fein, Founder & President, Pembroke Consulting Inc
CVS Caremark (CVS) launched its new Health Savings Pass, which allows customers to buy 90 day supplies of over 400 generics for $9.99 (after paying an enrollment fee of $10). The new program sounds like a logical pre-emptive strike against anticipated share losses. Translation: an old-fashioned, race-to-the-bottom...
November 11, 2008
Roche's Tarceva offers a competitor to Lilly's Alimta
Analysis of: Roche Says Tarceva Data Promising | online.wsj.com
Author: GLG Expert Contributor
Tarceva can maintain a remission in non small cell lung cancer after initial therapy with other agents. Just like Lilly's Alimta
November 11, 2008
Increased use of Zevalin, Bayer ( & by osmosis Bexxar, GSK) in low grade lymphomas
Analysis of: Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma | jco.ascopubs.org
Author: GLG Expert Contributor
Addition of Zevalin after a CR or PR in low grade, follicular lymphomas adds to CR rates and improves time to progression. The implication is that this will result in improved survivals.

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 661

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T13:45:17.613